RxDoctor Payments Data

Matthew Traynor, MD

Glaucoma Specialist · Idaho Falls, IDNPI 1063563823

Payments from drug & device makers

$1,632in general payments, 2019–2025

Across 45 payments — averaging $36.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$461
  • Sight Sciences, Inc.$349
  • Bausch & Lomb Americas Inc.$183
  • AbbVie$146
  • NEW World Medical,inc.$111
  • Biotissue Holdings Inc.$90
  • plus $293 from 9 others
$14,400in research payments, 2019–2025

Across 4 payments — averaging $3600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sight Sciences, Inc.$14K

What the payments were for

  • Food & beverage$1,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$393,619
Medicare patients
778
Services billed
3,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod63$30,890
RestasisCyclosporine26$20,667
SimbrinzaBrinzolamide/Brimonidine Tart74$16,796
LumiganBimatoprost49$16,652
RhopressaNetarsudil Mesylate45$16,438
CombiganBrimonidine Tartrate/Timolol33$13,623
Prednisolone Acetate348$13,428
Latanoprost1,688$12,828
RocklatanNetarsudil Mesylat/Latanoprost33$11,231
Dorzolamide-TimololDorzolamide/Timolol/Pf71$10,238
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat707$9,764
Brinzolamide48$5,630
Cyclosporine13$4,623
TafluprostTafluprost/Pf28$4,286
Brimonidine Tartrate293$2,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$146$50,942108 claims
Bausch & Lomb Americas Inc.Vyzulta$183$30,89063 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$22$27,66978 claims
AlconSimbrinza$461$16,79674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Idaho Falls

Where these figures come from

Is this you, or does something look wrong? →